IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D

NCT ID: NCT02635282

Last Updated: 2017-03-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2017-03-23

Brief Summary

The general objective of this study is to determine whether intranasal ketamine should be incorporated into formulary as an option to treat pain during minor procedures in the pediatric emergency department.

Detailed Description

In the pediatric emergency department, one of the main goals in patient care is to provide adequate pain management. Many patients present to the emergency department with conditions or injuries that cause acute or chronic pain. Health care providers routinely aim to treat patients' pain in a timely manner after arrival to the emergency department. A common scenario occurs when a patient presents with a condition in which treatment will require that a potentially painful or anxiety-provoking procedure will be performed in the ED, and providers also strive to treat this pain and anxiety accordingly. There are several different methods for treating pain and anxiety, including multiple types of medications, which can be given orally, intravenously, intramuscularly, or intranasally. The use of intranasal medications for the treatment of pain and anxiety has been steadily increasing over the last decade, and this has been particularly helpful in the pediatric population. There are several advantages of using intranasal medications, including rapid onset, ease of administration, and lack of need for IV access.

At this time, this pediatric emergency department uses two different medications via the intranasal route of administration: fentanyl, a synthetic opiate, and midazolam, a benzodiazepine, which are used for pain control and anxiolysis, respectively, and these two medications are frequently used together. The objective of this study is to introduce ketamine as a third medication for intranasal use and to observe its effects on pain control; this medication is currently used either intravenously or intramuscularly in the investigator's ED. Ketamine is an anesthetic that has properties of analgesia and amnesia and has a generally favorable side effect profile. This study will observe the effects of using a medication that is already widely used in the investigator's ED, but it will be used via a different route of administration, offering advantages over other options. In this study, patients will be enrolled who have been diagnosed with a soft tissue abscess that will be treated with incision and drainage in the ED. Patients in one group will be given a dose of intranasal ketamine at a predetermined dose, and measured variables will include pain score, vital signs, patient and/or parent satisfaction, adverse effects, length of stay, and need for additional doses of ketamine or additional medications. This group of patients will be compared with another group of patients who will be given intranasal fentanyl and intranasal midazolam using a randomization through the RedCap system. The investigators hypothesize that the use of intranasal ketamine in this PED for treating pain associated with the minor procedure of incision and drainage of a soft tissue abscess will provide satisfactory pain control in these patients while offering advantages over other treatment options, as compared with patients treated with the current standard intranasal medications.

Conditions

Abscess; Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IN fentanyl and midazolam

group of patients who are randomized to receive intranasal fentanyl and midazolam

Group Type: ACTIVE_COMPARATOR

intranasal fentanyl

Intervention Type: DRUG

intranasal midazolam

Intervention Type: DRUG

IN ketamine

group of patients who are randomized to receive intranasal ketamine

Group Type: EXPERIMENTAL

intranasal ketamine

Intervention Type: DRUG

Interventions

intranasal ketamine

Intervention Type: DRUG

intranasal fentanyl

Intervention Type: DRUG

intranasal midazolam

Intervention Type: DRUG

Other Intervention Names

Versed

Eligibility Criteria

Inclusion Criteria

• Diagnosis of abscess with planned incision and drainage of a single abscess

Exclusion Criteria

• Fast Track patients
• Patients who have received an opioid analgesic within the previous 4 hours of time of enrollment in study
• Patients with parent or legal guardian not present to give informed consent for enrollment in study
• Non-English speaking patients and/or parent
• Patients with a contraindication for the administration of intranasal medication (nasal trauma, aberrant nasal anatomy)
• Patients with ocular injuries
• Patients with a known allergy to ketamine, fentanyl, and/or midazolam
• Pregnant females
• Patients with history of seizure disorders

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Tennessee

OTHER

Sponsor Role: lead

Responsible Party

Cynthia Copley

Principal Investigator, Pediatric Emergency Medicine Fellow

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Countries

United States

References

Bailey B, Gravel J, Daoust R. Reliability of the visual analog scale in children with acute pain in the emergency department. Pain. 2012 Apr;153(4):839-842. doi: 10.1016/j.pain.2012.01.006. Epub 2012 Feb 4.

Reference Type: BACKGROUND

PMID: 22305630 (View on PubMed)

Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013 Feb 12;80(7):642-7. doi: 10.1212/WNL.0b013e3182824e66. Epub 2013 Jan 30.

Reference Type: RESULT

PMID: 23365053 (View on PubMed)

Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.

Reference Type: RESULT

PMID: 24127709 (View on PubMed)

Del Pizzo J, Callahan JM. Intranasal medications in pediatric emergency medicine. Pediatr Emerg Care. 2014 Jul;30(7):496-501; quiz 502-4. doi: 10.1097/PEC.0000000000000171.

Reference Type: RESULT

PMID: 24987995 (View on PubMed)

Other Identifiers

15-04113-FB

Identifier Type: -

Identifier Source: org_study_id